Drugmakers Mallinckrodt and Endo get a bump from tariffs

Drugmakers Mallinckrodt and Endo get a bump from tariffs in $6.7 billion merger
Mallinckrodt and Endo , drugmakers which recently emerged from bankruptcy after a wave of U.S. opioid lawsuits, announced plans Thursday to join forces in a deal valued at $6.7 billion.
Drugmakers Mallinckrodt and Endo Are in Talks to Merge
Mallinckrodt Pharmaceuticals and Endo Inc. are exploring a potential merger that could be valued at about $7 billion, people with knowledge of the matter said.
Drugmakers Mallinckrodt, Endo to Merge, Plan NYSE Listing
Dublin-headquartered Mallinckrodt is taking over smaller rival Endo and planning to list the combined firm on the New York Stock Exchange, the two drugmakers said Thursday.
Drugmakers Mallinckrodt and Endo to merge in nearly $7 billion deal
Mallinckrodt and Endo, drugmakers with a shared history of facing bankruptcy and U.S. opioid litigation, have agreed to merge in a deal valued at nearly $7 billion. Endo shareholders will get $80 million in cash and own 49.
Troubled Drugmakers Mallinckrodt, Endo Officially Announce $6.7B Merger
As per the Thursday release, Endo will be folded into Mallinckrodt, which will then continue as the holding entity for the combined companies. Post-merger, the company will be listed on the New York Stock Exchange and is projected to generate around $3.6 billion in revenue this year.
Drugmakers Mallinckrodt, Endo agree to merge in nearly $7 billion deal
Endo shareholders will get $80 million in cash and own 49.9 per cent of the combined company, while Mallinckrodt shareholders will own the rest for an enterprise value of $6.7 billion
Drugmakers agree to participate in second round of price negotiations
All drug manufacturers, including Novo Nordisk and Teva Pharmaceuticals , whose medicines are part of the second round of ...
STAT1d
U.K. plan to require drugmakers to pay higher rebates draws criticism from industry group
The U.K. government proposes raising mandatory drug rebates paid by drug companies to bolster the National Health Service.
Medical Marketing & Media2d
How Trump’s federal healthcare funding cuts could impact pharma
Staff and funding cuts to the NIH, FDA and USAID could have downstream implications for R&D in the pharma industry, experts ...
Fierce Pharma2d
Breaking down pharma’s fourth-quarter sales boom
Despite a rocky start for many drugmakers at the start of last year, 2024’s fourth quarter saw just two of the top 25 global ...